Chemomab’s Positive Trial Results Boost Investor Confidence
Company Announcements

Chemomab’s Positive Trial Results Boost Investor Confidence

Chemomab Therapeutics (CMMB) has released an update.

Don't Miss out on Research Tools:

Chemomab Therapeutics reported promising results from its Phase 2 SPRING trial for CM-101, a potential treatment for primary sclerosing cholangitis, driving investor interest and strategic partnership discussions. The company secured $10 million in private placement funding, extending its cash runway to early 2026. Chemomab plans to advance CM-101 to a Phase 3 trial in late 2025, aiming to further capitalize on its promising pipeline.

For further insights into CMMB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyChemomab highlights clincial activity of CM-101 at The Liver Meeting 2024
TipRanks Auto-Generated NewsdeskChemomab Therapeutics Aligns Leadership Incentives with Shareholders
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App